AOTMiT: Transparency Council on a drug for ovarian cancer and NSCLC

The agenda is:

• Preparation of an opinion on the validity of including selected medical devices and medicinal products on the list of free drugs and medical devices for pregnant and postpartum women.
• Preparation of a position on the legitimacy of qualifying the provision of healthcare, intravitreal injection as a guaranteed service.

Preparation of positions on drug evaluation:

Lynparza (olaparibum) as part of the drug program: "Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer (ICD-10: C56, C57, C48)",

Tagrisso (osimertinibum) as part of the drug program: "Treatment of non-small or small cell lung cancer (ICD-10 C 34)".

Preparation of opinions on draft health policy programs of local government units:

"Early specialist and comprehensive care for a child at risk of disability or disabled from the area of ​​the Nędza Commune",

"Regional rehabilitation program for adolescents with depressive disorders" (Wielkopolskie Province).

Preparation of an opinion on reimbursement of drugs containing active substances:

haloperidol in the indication Huntington's disease.

olanzapine in the indication Huntington's disease,

prednisone in the indications of: myasthenia gravis; myasthenic syndrome; inflammatory myopathy; inflammatory neuropathy (except Guillain-Barré syndrome).

Source: AOTMiT